Healthcare Professionals
Continuous infusion - FAQs
Patient information
You can download the following files in PDF format :
Summary of Product Characteristics Prescribing Information Patient Information LeafletHow should KOGENATE® Bayer be administered as continuous infusion during major surgery?
How is the infusion rate calculated?
What equipment was used to infuse the KOGENATE® Bayer?
How should KOGENATE® Bayer be prepared for continuous infusion?
How much KOGENATE® Bayer was infused during the study?
Select a question from the left hand side of this page and the answer will appear here
How should KOGENATE® Bayer be administered as continuous infusion during major surgery?
Raise FVIII activity pre-surgery with an initial bolus infusion and immediately follow with continuous infusion (in IU/Kg/h)adjusting according to patient’s daily clearance and desired FVIII levels for at least seven days. 22
How is the infusion rate calculated?
Infusion rate
(in IU/Kg/h)
=
Clearance
(in ml/h/Kg)
X
Desired FVIII level
(in IU/ml)
reference 22
What equipment was used to infuse the KOGENATE® Bayer?
The low concentration factor was administered with the WalkMed® 350 ambulatory infusion pump and the high concentration factor was administered with the CADD PLUS pump. 19
How should KOGENATE® Bayer be prepared for continuous infusion?
KOGENATE® Bayer must be prepared under aseptic conditions. Under these conditions, in-use stability has been demonstrated for 48 hours. 22
How much KOGENATE® Bayer was infused during the study?
Mean total KOGENATE® Bayer infused into patients was 29,544 +/– 6,387 IU (range 19,350 – 42,240). 22
References
19. Luboshitz J et al.Hemophilia 2006 World Congress, Vancouver, Canada,May 21-25,2006.
22. KOGENATE® Bayer Summary of Product Characteristics, August 2010
Produced by Bayer. This website is intended for HealthCare professionals.
Date of preparation: December 2010
UK.PH.HN.KOG.2010.250.25.4